May 3, 2025 — Rather quietly this week, Eli Lilly and Company announced that it had withdrawn an application to FDA for an indication to use tirzepatide (Zepbound) in treating heart failure – specifically for HFpEF. This news came up in a briefing for investors, with Lilly’s Chief Scientific Officer, Dan Skovronsky, saying: “Following discussions with the FDA, we’ve […]
March 20, 2025 — It’s unmistakable. A quick look at the upcoming meeting of the American College of Cardiology in Chicago tells us that obesity care has a growing role in cardiology. The meeting starts March 29 and a total of 27 educational sessions will focus on obesity. Three late breaking publications – two for semaglutide and one for […]
February 7, 2025 — Novo Nordisk and Lilly reported on their business results this week for the final quarter of 2024. These reports brought clarity on a number of points, but to us, one thing stands out. We are moving from euphoria and hype about limitless possibilities in obesity to the realities of market competition and incremental progress. Sales […]
August 3, 2024 — One more chapter opened this week in the ongoing story of diseases that improve when healthcare providers effectively treat obesity. Lilly announced topline results from a study showing that tirzepatide cuts the rate of adverse heart failure outcomes in persons with obesity and heart failure by 38% when compared to placebo. The specific form of […]
April 8, 2024 — Obesity research never rests, it seems. Over the weekend, at the American College of Cardiology annual meeting and in the New England Journal of Medicine, we got a third confirmation of the benefit that semaglutide delivers to patients with obesity and heart failure. Specifically, this is about heart failure with preserved ejection fraction – HFpEF. […]
August 28, 2023 — On Friday, NEJM published impressive results in an RCT of semaglutide for treating patients who have obesity and heart failure with preserved ejection fraction (HFpEF). The treatment enabled these people to function better, feel better, and suffer half as many serious adverse events. These are important benefits for people with a very difficult condition. But […]
August 26, 2023 — Scientists who study semaglutide in obesity are producing a steady stream of impressive results. Yesterday in the New England Journal of Medicine, a randomized controlled trial in persons with obesity and heart failure with preserved ejection fraction demonstrated superior weight reduction, improvement in heart failure, better physical functioning, and a halving of serious adverse events. […]
